| 多西他赛治疗前列腺癌的研究进展 |
| |
| 引用本文： | 邓 姣,何仲明,刘飞能,欧译天,夏成兴,杨德林.多西他赛治疗前列腺癌的研究进展[J].现代肿瘤医学,2021,0(21):3855-3858. |
| |
| 作者姓名： | 邓 姣 何仲明 刘飞能 欧译天 夏成兴 杨德林 |
| |
| 作者单位： | 昆明医科大学第二附属医院泌尿外科,云南 昆明 650101 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81860453）;国家自然科学基金地区项目（编号:81860453） |
| |
| 摘 要： | 多西他赛是一种细胞毒性抗肿瘤药物，在前列腺癌中的疗效确切。对于激素敏感性前列腺癌，能明显提高高负荷转移性前列腺癌患者的总体生存期。对于去势抵抗性前列腺癌，可延缓癌症相关症状的进展。但多西他赛的严重不良反应常导致其使用受限制，适时联合用药可使患者获得较高的生存效益。本文对多西他赛治疗各类前列腺癌及其不良反应、应用时机的研究进行综述，以期为临床前列腺癌化疗提供参考。
|
| 关 键 词： | 多西他赛 前列腺癌 不良反应 应用时机 |
The progress of docetaxel for the treatment in prostate cancer |
| |
| DENG Jiao,HE Zhongming,LIU Feineng,OU Yitian,XIA Chengxing,YANG Delin.The progress of docetaxel for the treatment in prostate cancer[J].Journal of Modern Oncology,2021,0(21):3855-3858. |
| |
| Authors: | DENG Jiao HE Zhongming LIU Feineng OU Yitian XIA Chengxing YANG Delin |
| |
| Affiliation: | Department of Urinary Surgery,the Second Affiliated Hospital of Kunming Medical University,Yunnan Kunming 650101,China. |
| |
| Abstract: | Docetaxel is a cytotoxic antineoplastic drug in prostate cancer,which get definite efficacy in clinic.Docetaxel improve the overall survival of high-volume disease in hormone-sensitive prostate cancer.For castration-resistant prostate cancer,docetaxel would delay the progression of symptoms cancer-related.However,docetaxel is limited in clinic for its serious adverse reactions.Correct combination therapy in appropriate time would help patients obtain higher survival benefits.The review summarize the application,adverse reactions,and the using timing of docetaxel in different prostate cancer,in order to provide a reference for clinical prostate cancer chemotherapy. |
| |
| Keywords: | docetaxel prostate cancer adverse reactions application timing |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
|
